DcR2 and DR5 protein expression in prostate cancer cells when androgen action had been neutralised. (A) and (B): in LNCaP cells incubated for 4 days with ethanol vehicle as control (Ct) (0.001% was the highest concentration used) or R1881 at 0.1 nM or 10 nM, without or with 25 μM antiandrogen bicalutamide. (C) and (D): in PC3 cells, devoid of androgen receptor, incubated for 4 days with ethanol vehicle as control or increasing concentrations of R1881. All the samples were run and detected together, but some films were cut and pasted to remove spots from replicate cell protein extracts. Immunoblot results and histograms represent DcR2 and DR5 levels and were normalized to β-actin expression. The values represent the mean ± SD determined from triplicate cultures of a representative experiment from 2 independent experiments. For each protein a representative autoradiograph is shown. *P < 0.05 versus the other treatment conditions.